Utility of Interferon- Release Assay Results to Monitor Anti- Tubercular Treatment in Adults and Children
|
|
- Willis Higgins
- 5 years ago
- Views:
Transcription
1 Clinical Therapeutics/Volume 34, Number 5, 2012 Utility of Interferon- Release Assay Results to Monitor Anti- Tubercular Treatment in Adults and Children Elena Chiappini, MD, PhD, Francesca Fossi, MD, Francesca Bonsignori, MD, Sara Sollai, MD, Luisa Galli, MD, and Maurizio de Martino, MD Department of Science for Woman and Child s Health, Meyer Children s Hospital, University of Florence, Florence, Italy ABSTRACT Background: Interferon- release assays (IGRAs), including the commercially available T-SPOT.TB, QuantiFERON-TB Gold (QFT-G), and QuantiFERON- TB Gold In-Tube (QTF-G-IT), enable detection of circulating T lymphocytes responsive to specific Mycobacterium tuberculosis antigens. Studies of the potential role of serial IGRAs for assessment of response to anti-tubercular therapy are accumulating. Objective: The objective of this systematic review was to evaluate the potential clinical utility of serial IGRAs in anti-tubercular therapy. Methods: We conducted a literature search of the Cochrane Library and MEDLINE by PubMed, from database inception through October 1, 2011, for serial IGRA results in anti-tubercular therapy, in adults and children, using commercial stardardized assays. All types of articles in the English language were included. Meta-analysis was performed to estimate the pooled percentage of reversion from a positive to a negative IGRA value at 3- to 6-month follow-up. Results: According to inclusion and exclusion criteria, three T-SPOT.TB based (n 319 patients), three QFT-G based (n 75 patients), and seven QFT-G-ITbased (n 558 patients) longitudinal studies were included. The percentage of patients with reversion from a positive to a negative IGRA value ranged from 5.71% to 13.93% for T-SPOT.TB, 5.26% to 71.05% for QFT-G, and 14.28% to 41.89% for QFT-G-IT assays. Meta-analysis estimation of reversion was feasible only for the QFT-G-IT assay, at 30.54% (95% CI, ). In two pediatric studies, which were QFT-G-IT based (n 122 children), the reported reversion rates were 14.28% and 20.33%, respectively. Conclusions: Because IGRAs require time and cost resources, and reversion from positive to negative IGRA values occurs in a minority of treated patients, monitoring IGRA changes over time seems to have only speculative value in adults. Data in children are poor, but are in line with results reported in adults. (Clin Ther. 2012;34: ) 2012 Elsevier HS Journals, Inc. All rights reserved. INTRODUCTION The availability of interferon- (IFN- ) release assays (IGRAs) offers new possibilities for the diagnosis of tuberculosis (TB). IGRAs including the commercially available assays T-SPOT.TB (T-SPOT; Oxford Immunotec, Ltd., Abingdon, Oxfordshire, England), and QuantiFERON-TB Gold (QFT-G) and QuantiFERON-TB Gold In-Tube (QFT-G-IT) (both from Cellestis, Ltd., Carnegie, Victoria, Australia), enable detection of circulating T cells responsive to specific Mycobacterium tuberculosis antigens. False-positive results described with the use of the tuberculin skin test due to previous Bacille Calmette Guérin (BCG) vaccination or to infections with nontuberculous mycobacteria are thought to be averted or minimized using IGRAs. 1 4 Accordingly, higher specificity of IGRA with respect to the tuberculin skin test has been reported in adults and children. 5 8 Moreover, in contrast to the tuberculin skin test, IGRAs can be repeated without concerns about sensitization and boosting, and only one visit is required. Emerging data suggest a potential role for IGRAs in monitoring the response to anti-tubercular therapy IGRAs rely on a short period of incubation ( 24 hours), and detect the response of activated effector T lymphocytes rapidly releasing IFN- after stimulation with specific antigen. 1 Conversely, central Accepted for publication March 19, doi: /j.clinthera /$ - see front matter 2012 Elsevier HS Journals, Inc. All rights reserved. May
2 Clinical Therapeutics memory T cells produce effector cytokines within several days. Thus, a positive IGRA result should be due to a present infection and not to a remote memory. 1 Because the effector response is driven by the antigen load, it has been suggested that the number of effector T lymphocytes is increased in the presence of active mycobaterial replication such as active disease. Successful treatment is associated with a reduced antigen load and, subsequently, with a lower number of effector cells specific to M. tuberculosis antigen, leading to a reduction in IFN- production and possibly resulting in reversion of the IGRA result from positive to negative. 2 Studies of the significance and interpretation of IGRA results after anti-tubercular therapy are rapidly accumulating. To investigate the potential clinical utility of serial IGRAs in assessing the response to treatment, we reviewed the available literature. METHODS Definition of Reversion Reversion was defined as the presence of a positive baseline IGRA value and a negative follow-up IGRA result, according to the manufacturer s adopted cutoffs, as previously described. 1 8 Search Strategy We performed a literature search of the Cochrane Library and MEDLINE by PubMed, from database inception through October 1, 2011, using the following terms: IGRA[Title/Abstract] OR (Interferon-gamma[Title/Abstract] AND release[title/abstract] AND assay[title/abstract]) OR T-SPOT.TB[Title/Abstract] OR QuantiFERON[Title/Abstract] AND (follow- [Title/Abstract] AND up[title/abstract]) OR reversion[title/abstract] OR longitudinal[title/abstract]) AND (Humans[MeSH Terms] AND English[lang]. Limits were field [Title/Abstract], species [Humans], and language [English]. A similar search was also conducted of the EMBASE database, which yielded no additional pertinent studies. Bibliographies in all relevant articles were then evaluated, and pertinent articles were included. Study Selection After the primary search was conducted by reviewing titles and abstracts of studies, the full texts of eligible studies were screened for inclusion, and study quality was assessed using the MOOSE (Meta-analysis of Observational Studies in Epidemiology) checklist. 17 Relevant data were extracted and entered into tables. Study eligibility, quality assessment, and data extraction were checked for validity by a second author. An article was included in this review if it contained original data from adults or children or longitudinally evaluated changes in IFN- levels by using a commercial IGRA after 3 to 6 months of anti-tubercular therapy in latent TB infection (LTBI) or active TB. All patients with active TB should have received at least the classic 6-month course of therapy, starting with three or four classic anti-tubercular drugs (rifampicin, isoniazid, pyrazinamide, and/or ethambutol). According to disease severity and risk of resistance, other anti-tubercular therapies including second- or third-line drugs could have been used, as judged by the treating physician. Patients were classified as responders to treatment if after 6 months of specific anti-tubercular therapy the results of microbiologic cultures in appropriate specimens were negative and there was clinical and radiologic improvement, as determined by findings at chest radiography or computed tomography. All patients with LTBI should have received isoniazide for 9 months or isoniazide plus rifampicin for 3 months. Compliance should have been assessed during follow-up, or directly observed therapy should have been administered. Studies of serial IGRAs performed in individuals exposed to or infected with TB who were not receiving anti-tubercular therapy were excluded, as were crosssectional studies. Studies that originated from the same center were checked to ensure that the same data set was not replicated. Statistical Analysis For each selected study, the percentage of patients with reversion of IGRA values was reported, and 95% CIs were calculated. We attempted to perform a formal meta-analysis and calculate pooled estimates for the percentage of IGRA reversion from a positive to a negative value after 3 to 6 months of anti-tubercular therapy. Preliminary analyses showed that data from only three studies using QFT-G and another three studies using T.SPOT-TB were eligible (Figure 1), not allowing data from these assays to be pooled. Therefore, only data from eligible studies using QFT-G-IT were pooled in a formal meta-analysis. The percentages of reversion of IGRA values were pooled using the Der Simonian and Laird method using a random effects model to 1042 Volume 34 Number 5
3 E. Chiappini et al. Potentially relevant citations identified by electronic databases: 174 Excluded articles because not pertinent articles or duplicates: 145 Full text articles screened for further eligibility criteria: - In-house ELISPOT: 13 - T-SPOT.TB : 6 - QFT: 3 - QFT-G-IT: 9 Excluded articles according to inclusion/exclusion criteria: - In house ELISPOT: 13 - T-SPOT.TB: 3* - QFT-G-IT:2* Articles included in the systematic review: - T-SPOT.TB : 3 - QFT: 3 - QFT-G-IT: 7 (included in formal metaanalysis) *For cross-sectional design or because rates of reversion in treated and untreated patients were not provided separately Figure 1. Flow diagram for study selection. QFT, QuantiFERON-Gold assay; QFT-G-IT, QuantiFERON-Gold In-Tube assay. account for heterogeneity between studies. 18,19 The Cochran Q test was used to assess homogeneity between studies. 19 The magnitude of heterogeneity between studies was expressed as the variance percentage attributable to between-studies heterogeneity, the I 2 statistic. 19 Statistical analyses were performed using StatsDirect software ( RESULTS One hundred seventy-four articles were initially identified, of which 29 studies were initially selected for relevance and pertinence, according to the search strategy (Figure 1 and Table). At further assessment, two cross-sectional studies 20,21 and one study that did not separately provide data from treated and untreated patients 10 were excluded. Studies Using T-SPOT.TB Six studies using T-SPOT.TB were initially identified. 7,9,10,16,20,21 (Table). However, two studies including, respectively, 33 and 79 adults with active TB, had major limitations: longitudinal data from the same patient were not available, 20 and results obtained compared data from patients at the beginning of treatment with data from other patients still receiving or at the end of treatment. 21 In both of these studies, a lower percentage of negative T-SPOT.TB results was observed in treated versus untreated patients (83% vs 19%, 20 and 83.3% vs 69.8% 21 ; however, these data should be interpreted with caution because of the cross-sectional study design. In another study, a high variability in IGRA pattern response in 122 adults with LTBI tested using both QFT-G-IT and T-SPOT.TB was reported, with a strong concordance between the two tests ( ). 10 The overall percentage of individuals with a positive result remained stable at approximately 45% to 50%. A dynamic pattern of response with reversions or conversions occurred more often when T.SPOT-TB or QFT-G-IT results were intermediate (5 to 50 spots or IU/mL) than those observed in individuals with lower or higher values. 10 Of note, only 29.5% of these patients completed preventive isoniazide therapy, and data from treated and untreated patients could not be derived separately. 10 The percentage of patients with reversion at 6 months was 5.71% in one study from Switzerland that included 35 adults with active TB and positive T-SPOT.TB results at baseline, 9 and 10% in a study from the United States that included 40 adults with active TB. 7 T-SPOT.TB and QFT-G-IT were simultaneously used in another study that included 275 patients with active TB. The percentage of patients with reversion was higher for QFT-G-IT than for T-SPOT.TB (39.2% vs 13.9%). 16 May
4 Clinical Therapeutics Table. Characteristics of studies using a commercially available interferon- release assay (IGRA). Patients With Reversion of IGRA Values Source, Year Country Population No. (%) 95% CI Follow-Up, Mo T-SPOT.TB Ribeiro et al, United States Adults with active TB 4/40 (10.0) Bosshard et al, Switzerland Adults with active TB 2/35 (5.71) Chee et al, Singapore Adults with cultureconfirmed TB 34/244 (13.93) Dominguez et al, Spain Adults with active TB; cross-sectional study Dheda et al, Canada Adults with cultureconfirmed TB Franken et al, The Netherlands TST-positive adults with TB contacts Longitudinal data for same patient were not available Longitudinal data for the same patient available only for three patients Data from treated and untreated patients not derived separately QuantiFERON-Gold-TB Sauzullo et al, Italy Adults with active TB 27/38 (71.05) Kobashi et al, Japan Adults with active TB 9/18 (50.0) Goletti et al, Italy Adults with recent TB 1/19 (5.26) contact QuantiFERON-Gold-TB In tube Dyrholl-Riise et al, Norway Adults with LTBI 15/40 (37.50) Lee SH et al, South Korea Adults with LTBI 31/74 (41.89) Lee SW et al, South Korea Adults with active TB 18/57 (31.57) Bocchino et al, Italy Adults with cultureconfirmed 15/53 (28.30) TB Hermann et al, France Children with LTBI or 9/63 (14.28) active TB Nenadic et al, Croatia Children with LTBI or 12/59 (20.33) active TB Chee et al, Singapore Adults with cultureconfirmed TB 83/212 (39.15) Dominguez et al, Spain Adults with active TB; cross-sectional study Franken et al, The Netherlands TST-positive adult with TB contacts, data not available; TB, tuberculosis; LTBI, latent tuberculosis infection. Longitudinal data for same patient not available Data from treated and untreated patients not provided separately Studies Using QFT-G The QFT-G assay was the first commercially available ELISA-based assay, and subsequently was modified as the QFT-G-IT. Three studies using QFT-G were identified, 8,11,22 including a total of 75 patients with a positive result at baseline (Table). In a study from Italy, 11 a 70% reduction in IFN- levels at 6 months (from 17.5 [2.7] IU/mL to 1.3 IU/ ml; P ) was reported in 19 patients with TB; however, in only one patient (5.1%) did the value revert from positive to negative. In another study from Italy 22 that included 38 patients with active TB, IFN- levels significantly decreased (from a median value of 2.79 UI/mL to 0.02 UI/mL; P 0.001) at 6 months of therapy in 27 patients with reversion of IGRA values (71.1%) with clinical resolution, but remained stable 1044 Volume 34 Number 5
5 E. Chiappini et al. (median, 3.63 and 3.25 UI/mL, respectively; P 0.085) in 11 without reversion of values (28.9%) including 5 patients with clinical resolution and 6 in whom therapy failed. In a study from Japan, 8 reversion occurred after 6 months in 9 of 18 patients (50%) with active TB, without correlation with clinical response to treatment. Sustained IFN- levels persisted for at least 2 years after completion of treatment. Considered together, these findings suggest that it is not possible to categorize responders and non-responders to therapy according to the presence or absence of reversion of QFT-G results. Studies Using QFT-G-IT Nine studies were initially identified using QFT- G-IT. 1,2,6,10,13 16,21 However, data for treated patients were not separately provided in one, 10 and one study was cross-sectional. 22 (Figure 1). Thus, seven studies were finally included. In a study from Croatia, 1 35 of 40 patients (87.5% 84.6%) still had positive results of QFT-G-IT after 3 to 15 months of therapy. IFN- values were comparable at the start of the study (mean [SD] 6.13 [3.99] IU/mL) and after 3 and 15 months (5.65 [4.14] IU/mL), indicating that IGRAs should not be used as a reliable marker for monitoring the efficacy of therapy. 1 A decrease in IFN- levels was reported in 97.3% of 214 Korean subjects. 6 The authors of that study suggested that IGRA may be a useful tool for evaluating therapeutic response to rifampicin prophylaxis; however, reversion of test results occurred in only 41.9% of subjects. 6 In another large study from Singapore 16 in patients with active TB, a substantial percentage of patients had positive results of IGRA after treatment of TB, and the reversion rate was 39.2% (83 of 212 patients) with QFT-G-IT, and 13.9% (34 of 244) with T.SPOT-TB. The kinetics of the quantitative T-cell responses was not significantly different between patients with and without risk factors for disease relapse. 16 Studies In Children Commercial IGRAs (QFT-G-IT) have been used in two pediatric studies, 2,15 overall including 122 children. In one study, children with LTBI and active TB experienced a similar and significant rebound at day 10 of treatment, with higher IFN- values than those at baseline (P 0.035). 2 A subsequent decline in IFN- response was observed at days 0 and 90 or 180 (P 0.942); however, reversion occurred only in a minority of patients, 9 of 63 (14.3%). 2 In a study of 59 Croatian children aged 4 to 18 years, investigated before and after completion of anti-tubercular therapy, no difference was found in IFN- concentration between children with LTBI or active TB, neither before nor after treatment (mean [SD] at baseline, 4.43 IU/mL for LTBI, and 3.48 for active TB, and at follow-up, 2.04 for LTBI, and 1.51 for active TB (P and P 0.177, respectively). 15 The reported reversion rate was 20.33% (12 of 59 children) (Table). Results of Meta-Analyses Based on the results from seven QFG-IT studies, overall including 558 patients with TB with positive IGRA results at baseline, a meta-analysis estimate of the pooled percentage of patients with reversion of IGRA values after 3 to 6 months of anti-tubercular treatment for QFT-G-IT was calculated (Table). This pooled estimated percentage of reversion was 30.54% (95% CI, ) for QFT-G-IT (Figure 2). Inconsistency (I 2 ) was 70.8% (95% CI, 31.2% 86.3%). DISCUSSION To our knowledge, this is the first systematic review to explore the available data regarding changes in IGRA response during anti-tubercular therapy in adults and children. A significant decrease in IFN- production during anti-tubercular therapy have been reported in several studies. 2,6,8 However, even when present, variations in IFN- levels may vary largely between individuals, and reversion to negative values occurred only in a minority of patients. For QFT-G-IT and T-SPOT.TB, the rate of reversion ranged from 14% to 42% and from 6% to 14%, respectively. 7 9,11,12,16 Several factors may explain the low reversion rates observed in our review. Reinfection with M. tuberculosis, in particular in high-burden settings, or continuous exposure to environmental mycobateria expressing ESAT-6 or CFP-10 homologues 20 is a possible explanation for the persistent IGRA positivity despite effective therapy. Alternatively, it is possible that circulating effector T cells may persist for a long time after clearance of the infection. 20 In addition, several factors may interfere with the IGRA response, including endotoxin contamination, ethnic and nutritional characteristics of the patients, and HIV or helminth co-infection. 20 An intriguing possibility is that, at least in a subgroup of patients without reversion, persistent IGRA positivity is due to lack of sterilization, and it May
6 Clinical Therapeutics Author, Year Percentage (95%CI) n/n Bocchino, et al 14, ( ) 15/40 Dyrholl Riise, et al 1, 2010 Chee, et al 16, 2010 Herrmann, et al 2, 2009 Lee SH, et al 6, 2010 Lee SW, et al 13, 2010 Nenadic, et al 15, 2011 Pooled studies 0.42 ( ) 0.32 ( ) 0.28 ( ) 0.14 ( ) 0.25 ( ) 0.39 ( ) 0.31 ( ) 31/74 18/57 15/53 9/63 15/59 83/ Percentage (95% CI) Cochrane Q, (df = 6) P = Inconsistency (I 2 ) = 70.8% (95% CI: 31.2% 86.3%) Figure 2. Forest plot shows percentage of patients with reversion in longitudinal studies using one of the commercially available interferon- release assays (IGRAs): T-SPOT.TB, QuantiFERON-Gold, and QuantiFERON-Gold In-Tube. Squares and horizontal lines correspond to the recorded percentage of patients with reversion of IGRA values at 3- to 6-month follow-up in patients with tuberculosis with positive IGRA results at baseline, and their respective 95% CIs. Squares reflect the weight each study contributed to the analysis. The diamond represents the pooled value, and correspondent 95% CI. n/n, number of patients with reversion and total number of patients with a positive IGRA value at baseline. may be a hallmark of failure of therapy. Encouraging results in this regard were described in 2004in a small study from Italy based on an in-house ELISPOT (ELISA spot assay) that demonstrated reversion in patients with clinical response to anti-tubercular therapy but not in those exhibiting clinical failure. 23 However, subsequent large studies failed to demonstrated different percentages of reversion between patients with or without clinical response to treatment. 16 The biological explanation for reversion is unclear. Some authors have speculated that reversion may be due not only to a reduction in IFN- producing antigen-specific effector T cells during effective treatment, but that reversion may also reflect biological fluctuations in IFN- production or variability in laboratory procedures. 24 In addition, they may be influenced by the life cycle of M. tuberculosis, with phases of active replication and of the dormant state, associated with variations in the amount of secreted antigens such as ESAT-6 and CFP Inasmuch as IGRAs require time and cost resources, and interpretation of minimal variation in the IFN- level does not lead to change in clinical management of patients, based on our results, monitoring of IGRA changes over time seems to have only speculative value in adults. Data in children are limited. It has been reported that IGRA performance may vary largely between adults and children. 18 For example, higher percentages of indeterminate results in children compared with adults have been reported by some authors 26 but not confirmed by others. 27 IGRA results may be influenced by the child s age and immunologic status, including both physiologic immaturity and primary or acquired immunodeficiency. 26 The two pediatric studies selected in this review, both of which used the QFT-G-IT assay, reported a reversion rate of 14.3% and 20.3%, respectively, which suggests that in children, as in adults, serial IGRAs are not reliable for monitoring response to therapy One study has reported increased IFN- levels followed by a subsequent decrease. 2 The first rebound might confirm the potential of IGRA to detect recently acquired infection. Antitubercular therapy may restore active T-cell response, as noted in vivo in the TB paradoxic reaction, leading 1046 Volume 34 Number 5
7 E. Chiappini et al. to sustained IFN- production even in the presence of a lower bacterial burden. 2 The present review has several limits. Our search strategy may have resulted in some studies being missed because the decision to include only studies published in English may have excluded some data. In addition, we decided to include only data from studies based on commercial standardized IGRAs, excluding results from 13 articles using an in-house ELISPOT assay (data not shown). Methods and cutoffs in these studies were heterogeneous. Increased or persistently positive IFN- levels during and after treatment have been reported by some authors 27 but not confirmed by others. 12,23,28 Again, the clinical utility of such decay as a surrogate marker of treatment efficacy has been questioned because in half of the pediatric 3 and adult 5 patients, ELISPOT results remained positive at the completion of treatment of TB. Together, these findings are in line with those reported in our systematic review of studies using commercial IGRAs. Another possible limitation of our study is that results in patients with LTBI were not differentiated from results in those with active TB because only three studies directly compared these two populations. 1,2,15 In particular, one study in adults and two studies in children found no difference in IFN- dynamics between patients with LTBI or active TB. 1 Finally, the present review did not examine other interesting issues that may arise from studies of serial IGRAs such as the frequency and possible significance of conversion from a negative to a positive value, the IGRA predictive value for developing TB in exposed subjects, and the possible significance of the different dynamics of response to ESAT-6 and CFP-10 antigens. Each of these issues deserves a separate in-depth study. CONCLUSIONS Available data are now sufficient to suggest that, from a practical point of view, monitoring changes in IGRA response during anti-tubercular treatment is of limited usefulness in adults. Data in children are poor, but are in line with results reported in adults. ACKNOWLEDGMENTS This study was supported by Young Researcher Award, 2007, from the Italian Ministry of Health. Drs. Chiappini, Fossi, Bonsignori and de Martino were responsible for the study concept and design. Drs. Chiappini and Fossi were responsible for the literature search. Drs. Sollai and Bonsgnori were responsible for undertaking the statistical analyses. Drs. Chiappini and Fossi drafted the manuscript, and all authors critically participated in discussions about the design of the study, the choice of statistical analyses and interpretation of the findings and reviewing the manuscript. CONFLICTS OF INTEREST The authors have indicated that they have no conflicts of interest regarding the content of this article. REFERENCES 1. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, et al. Diagnosis and follow-up of treatment of latent tuberculosis: the utility of the QuantiFERON-TB Gold In-Tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis. 2010;10: Herrmann JL, Belloy M, Porcher R, et al. Temporal dynamics of interferon-gamma responses in children evaluated for tuberculosis. PLoS One. 2009;4:e Connell TG, Davies MA, Johannisen C, et al. Reversion and conversion of Mycobacterium tuberculosis IFN- ELISpot results during anti-tubercular treatment in HIV-infected children. BMC Infect Dis. 2010;10: Nicol MP, Piennar D, Wood K, et al. Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. Clin Infect Dis. 2005;40: Adetifa IM, Ota MO, Walther B, et al. Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases. PLoS One. 2010;5:e Lee SH, Lew WJ, Kim HK, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir Med. 2010;104: Ribeiro S, Dooley K, Hackman J, et al. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis. 2009;9: Kobashi Y, Sugiu T, Ohue Y, et al. Long term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease. Intern Med. 2008;47: Bosshard V, Roux-Lombard P, Perneger T, et al. Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis? Respir Med. 2009;103: Franken WP, Arend SM, Thijsen SF, et al. Interferongamma release assays during follow-up of tuberculin skin May
8 Clinical Therapeutics test-positive contacts. Int J Tuberc Lung Dis. 2008;12: Goletti D, Parracino MP, Butera O, et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1- epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res. 2007;8: Aiken AM, Hill PC, Fox A, et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis. 2006;6: Lee SW, Lee CT, Yim JJ. Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis. 2010; 10: Bocchino M, Chairadonna P, Matarese A, et al. Limited usefulness of QuantiFERON-TB Gold In-Tube for monitoring anti-tuberculosis therapy. Respir Med. 2010;104: Nenadic N, Kirin BK, Letoja IZ, et al. Serial interferon-g release assay in children with latent tuberculosis infection and children with tuberculosis. Pediatr Pulmonol. 2011;10: Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis specific antigens. Eur Respir J. 2010;36: Stroup DF, Berlin JA, Morton SC, et al; Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000; 283: Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J. 2011;30: Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a meta-analysis. Chest. 2010;137: Dheda K, Pooran A, Pai M, et al. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. J Infect. 2007;55: Dominguez J, De Souza-Galvao M, Ruz-Manzano J, et al. T-cell responses to the Mycobacterium tuberculosis specific antigen in active tuberculosis patients at the beginning, during, and after anti-tuberculosis treatment. Diagn Microbiol Infect Dis. 2009;63: Sauzullo I, Mengoni F, Lichtner M, et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One. 2009;4:e Hill PC, Brookes RH, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoSMed. 2007;4:e Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis. 2009;13: Carrara S, Vincenti D, Petrosillo N, et al. Use of A T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis. 2004; 38: Pavić I, Topić RZ, Raos M, et al. Interferon- release assay for the diagnosis of latent tuberculosis in children younger than 5 years of age. Pediatr Infect Dis J. 2011;30: Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics. 2009;123:e Ferrand RA, Bothamley GH, Whelan A, Dockrell HM. Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after antituberculosis treatment. Int J Tuberc Lung Dis. 2005;9: Address correspondence to: Elena Chiappini, Department of Science for Woman and Child s Health, Meyer Children s Hospital, University of Florence, Viale Pieraccini, 24, 50100, Florence, Italy. elena.chiappini@unifi.it 1048 Volume 34 Number 5
Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationClinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission Setting
Pulmonary Medicine Volume 2012, Article ID 757152, 6 pages doi:10.1155/2012/757152 Clinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission
More informationQuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients
Jpn. J. Infect. Dis., 70, 502 506, 2017 Original Article QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients Thana Khawcharoenporn 1 *, Benjawan Phetsuksiri 2, Janisara
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationKinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with tuberculous meningitis
ORIGINAL ARTICLE Korean J Intern Med 214;29:793-799 http://dx.doi.org/1.394/kjim.214.29.6.793 Kinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationCHEST. T-cell interferon- g release assays (IGRAs), such as. Original Research
CHEST Original Research Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area A Controlled
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationPersistently Retained Interferon-Gamma Responsiveness in Individuals with a History of Pulmonary Tuberculosis
Tohoku J. Exp. Med., 2014, 233, 123-128 The Response of IGRA Is Persistently Retained 123 Persistently Retained Interferon-Gamma Responsiveness in Individuals with a History of Pulmonary Tuberculosis Kwang
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTime interval to conversion of interferon-c release assay after exposure to tuberculosis
Eur Respir J 2011; 37: 1447 1452 DOI: 10.1183/09031936.00089510 CopyrightßERS 2011 Time interval to conversion of interferon-c release assay after exposure to tuberculosis S.W. Lee*,#, D.K. Oh ", S.H.
More informationAnalysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy
Jpn. J. Infect. Dis., 64, 133-138, 2011 Original Article Analysis of an Interferon-Gamma Release Assay for Monitoring the Efficacy of Anti-Tuberculosis Chemotherapy Kiyoko Takayanagi, Misako Aoki, Kumiko
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationIMMUNOLOGY & MEDICAL MICROBIOLOGY
RESEARCH ARTICLE Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis Lin Sun, Jing Xiao, Qing Miao, Wei-xing Feng, Xi-rong Wu, Qing-qin Yin, Wei-wei Jiao, Chen Shen,
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized
More informationInvestigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00730-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Investigation of false-positive
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationPredictive values of IGRAs and TST for progression to active disease in TB. 3 rd Global IGRA Symposium January 2012.
Predictive values of IGRAs and for progression to active disease in TB contacts in Singapore Cynthia B E Chee 1, K W KhinMar 1, S H Gan 1, J Cutter, T M Barkham, Y T Wang 1 1 TB Control Unit, Tan Tock
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationPost-treatment change in Mycobacterium tuberculosis antigenstimulated tumor necrosis factor-alpha release in patients with active tuberculosis
Brief Report Post-treatment change in Mycobacterium tuberculosis antigenstimulated tumor necrosis factor-alpha release in patients with active tuberculosis Chang Ho Kim, Seung Soo Yoo, Shin Yup Lee, Seung
More informationImmediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2672 2676 Vol. 48, No. 8 0095-1137/10/$12.00 doi:10.1128/jcm.00482-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Immediate Incubation
More informationInterferon-gamma release assay for treatment monitoring of active tuberculosis
JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02278-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-gamma
More informationTuberculosis (TB) elimination is part of the
Eur Respir J 20; 37: 00 DOI: 0.83/0903936.00480 CopyrightßERS 20 Interferon-c release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis M. Sester*, G. Sotgiu*, C. Lange,
More informationReceived 17 March 2011/Returned for modification 18 April 2011/Accepted 15 June 2011
CLINICAL AND VACCINE IMMUNOLOGY, Aug. 2011, p. 1378 1386 Vol. 18, No. 8 1556-6811/11/$12.00 doi:10.1128/cvi.05037-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Effect of Chemotherapy
More informationCritical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings
Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings by John Metcalfe Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy
More informationTitle: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
Author's response to reviews Title: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study Authors: Delia Goletti (d.goletti@tiscali.it)
More informationIGRAs for Diagnosis of Tuberculosis: 2010 Update
IGRAs for Diagnosis of Tuberculosis: 2010 Update Nira Pollock, M.D., Ph.D. Division of Infectious Diseases Beth Israel Deaconess Medical Center Boston, MA May 1, 2010 Problems with the PPD False positives
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More information(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationWithin-Subject Variability of Mycobacterium tuberculosis-specific Gamma Interferon Responses in German Health Care Workers
CLINICAL AND VACCINE IMMUNOLOGY, July 2011, p. 1176 1182 Vol. 18, No. 7 1556-6811/11/$12.00 doi:10.1128/cvi.05058-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Within-Subject
More informationChildren in contact with adults with
Eur Respir J 13; 41: 644 648 DOI: 1.1183/931936.12212 CopyrightßERS 13 Use of tuberculin skin test, IFN-c release assays and IFN-c-induced protein-1 to identify children with TB infection Mohammed A. Yassin*,#,
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationRichard N. van Zyl-Smit 1, Rannakoe J. Lehloenya 1,2, Richard Meldau 1, Keertan Dheda 1,3,4. Introduction
Original Article Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT. TB and QFT-GIT) Richard N. van Zyl-Smit
More informationFactors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis
http://dx.doi.org/10.4046/trd.2012.72.5.416 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:416-425 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationThe tuberculin skin test (TST) was until recently the
Rapid diagnosis of Mycobacterium tuberculosis infection in children using interferon-gamma release assays (IGRAs) Shahla Riazi, M.D., 1,2 Barbara Zeligs, 1,2 Henry Yeager, M.D., 3 Stephen M. Peters, Ph.D.,
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationAccuracy of enzyme-linked immunospot assay for diagnosis of pleural tuberculosis: a meta-analysis
Accuracy of enzyme-linked immunospot assay for diagnosis of pleural tuberculosis: a meta-analysis Z.Z. Li 1, W.Z. Qin 1, L. Li 1, Q. Wu 1 and Y.J. Wang 1,2 1 West China School of Medicine/West China Hospital,
More informationLatent tuberculosis (TB) infection (LTBI), a
COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,
More informationLimited usefulness of QuantiFERON-TB Gold In-Tube Ò for monitoring anti-tuberculosis therapy
Respiratory Medicine (2010) 104, 1551e1556 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Limited usefulness of QuantiFERON-TB Gold In-Tube Ò for monitoring anti-tuberculosis
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationAdachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal
Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal RESEARCH Open Access Tuberculosis examination using whole blood interferon-gamma release assay among health care workers in a Japanese hospital
More informationThe World Health Organization s strategy. Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts
Eur Respir J 21; 36: 594 6 DOI: 1.1183/931936.17159 CopyrightßERS 21 Enhanced diagnosis of HIV-1-associated tuberculosis by relating T-SPOT.TB and CD4 counts T. Oni*,#, J. Patel ", H.P. Gideon*, R. Seldon*,
More informationPredictive value for progression to tuberculosis by IGRA and TST in immigrant contacts
Eur Respir J 2010; 35: 1346 1353 DOI: 10.1183/09031936.00098509 CopyrightßERS 2010 Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts S.V. Kik*,#, W.P.J. Franken ",
More informationWhat is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries?
REVIEW What is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries? Peter Daley & Poorvi Chordia Author for correspondence Department of Medicine Unit
More informationDiagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs)
Diagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs) Educational aims To provide an overview of interferon- release assays (IGRAs) used for detection of tuberculosis
More informationCurr Opin Pulm Med 15: ß 2009 Wolters Kluwer Health Lippincott Williams & Wilkins
T-cell interferon-g release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings Keertan Dheda a,b,c, Richard van Zyl Smit a, Motasim Badri a and
More informationIndeterminate test results of T-SPOT TM.TB performed under routine field conditions
Eur Respir J 2008; 31: 842 846 DOI: 10.1183/09031936.00117207 CopyrightßERS Journals Ltd 2008 Indeterminate test results of T-SPOT TM.TB performed under routine field conditions P. Beffa*, A. Zellweger
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationKJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive
More informationInterferon gamma release assays for tuberculosis and their potential as efficacy markers for intervention trials Adetifa, I.M.O.
UvA-DARE (Digital Academic Repository) Interferon gamma release assays for tuberculosis and their potential as efficacy markers for intervention trials Adetifa, I.M.O. Link to publication Citation for
More informationEvidence-Based Comparison of Commercial Interferon- g Release Assays for Detecting Active TB
CHEST Special Feature Evidence-Based Comparison of Commercial Interferon- g Release Assays for Detecting Active TB A Metaanalysis Roland Diel, MD, MPH ; Robert Loddenkemper, MD, FCCP ; and Albert Nienhaus,
More informationCOMPARISON OF TWO INTERFERON-G ASSAYS AND
3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationClinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationDiagnosis and treatment of latent tuberculosis infection: an update
Curr Respir Care Rep (2013) 2:199 207 DOI 10.1007/s13665-013-0064-y RESPIRATORY INFECTIONS (CL DALEY, SECTION EDITOR) Diagnosis and treatment of latent tuberculosis infection: an update Anna K. Person
More informationThe Prevalence Rate of Tuberculin Skin Test Positive by Contacts Group to Predict the Development of Active Tuberculosis After School Outbreaks
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2015.78.4.349 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:349-355 The Prevalence Rate of Tuberculin Skin Test Positive by Contacts
More informationShort-Term Reproducibility of a Commercial Interferon Gamma Release Assay
CLINICAL AND VACCINE IMMUNOLOGY, Aug. 2009, p. 1170 1175 Vol. 16, No. 8 1556-6811/09/$08.00 0 doi:10.1128/cvi.00168-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Short-Term
More informationThe Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers
ORIGINAL ARTICLE The Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers Masaki Tanabe 1, Akiko Nakamura 1, Akie Arai 1, Daisuke Yamasaki
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationInterferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients
NDT Advance Access published January 22, 2009 Nephrol Dial Transplant (2009) 1 of 5 doi: 10.1093/ndt/gfn748 Original Article Interferon-gamma release assays versus tuberculin skin testing for detection
More informationT-Cell Assays for Tuberculosis Infection: Deriving Cut- Offs for Conversions Using Reproducibility Data
T-Cell Assays for Tuberculosis Infection: Deriving Cut- Offs for Conversions Using Reproducibility Data Anandharaman Veerapathran 1,2, Rajnish Joshi 1,2,3, Kalyan Goswami 1,2, Sandeep Dogra 4, Erica E.
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationAT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK
HOW WELL DO IGRAS PERFORM IN THE IDENTIFICATION OF PERSONS WHO ARE AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Dr Pranab Haldar MD MRCP Senior Lecturer and Consultant Physician University Hospitals of Leicester
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationIs the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center
Microbiology and Infectious Disease / QuantiFERON-TB Assay for TB Screening Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at
More informationPrevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia
RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:
More informationTesting & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?
NECHA 11/4/2016 Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat? E. Jane Carter, M.D. Immediate Past President International Union Against TB and Lung Disease
More informationDiagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients
CLINICAL RESEARCH STUDY Diagnostic Usefulness of a T-cell-based Assay for Extrapulmonary Tuberculosis in Immunocompromised Patients Sung-Han Kim, MD, a,b,c Kyoung-Ho Song, MD, a Su-Jin Choi, MS, b Hong-Bin
More information